drugset / Trial / NCT04191681

Safety and Efficacy of ARNI After LVAD ImplanT (SEAL-IT) Study

NCT04191681

Phase 4 Recruiting 50 enrolled The Cleveland Clinic
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to evaluate how well tolerated and effective an angiotensin receptor-neprilysin inhibitor (sacubitril-valsartan) is in patients with contemporary durable continuous flow left ventricular assist device (CF-LVAD) implantation compared to usual care oral vasodilator therapy.

Timeline

Start
2019-11-08
Primary completion
2022-03
Completion
2022-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Sacubitril-Valsartan Unknown 24 mg Oral
Subject Sacubitril-Valsartan Unknown 26 mg Oral